Ambrx Biopharma, Inc.

AMAM

Explore Our Financial Data > Companies > > Ambrx Biopharma, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	AMAM
CIK	0001990550
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	10975 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037
Website	ambrx.com
Phone	(858) 875-2400
CEO	Daniel J. OConnor
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	N/A
Net Income	N/A
Net Income to Common	N/A
EPS	N/A

View All

Balance Sheet

Cash	N/A
Assets	N/A
Liabilities	N/A
Common Equity	N/A
Liabilities & Equity	N/A

View All

Cash Flow Statement

Net Income	N/A
Cash From Operating Activities	N/A
Cash From Investing Activities	N/A
Cash From Financing Activities	N/A
Change in Cash	N/A

View All

Calculations

NOPAT	N/A
EBITDA	N/A
Price to Earnings	N/A
Price to Book	N/A
ROE	N/A

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O’Connor, Chief Executive

Article Link

Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for $2 Billion

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.

Article Link

Ambrx Announces Sale to Johnson & Johnson

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. “We are excited to reach this agreement with Johnson & Johnson for advancin

Article Link

Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023. “2023 has been a transformational year for Ambrx, especially for our publicly held securities. We voluntarily transferred to Nasdaq from the New York Stock Exchange, we changed our parent company domicile to Delaware from the Cayman Islands and

Article Link

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose Cohort 8 The cohort (2.88 mg/kg) is now fully enrolled with 20 patients Recommended phase 2 dose expected by early next year SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:

Article Link